As of 11/16/2020, Emgality has the best-in-class* commercial access for the preventive treatment of migraine1,2
*Best-in-class commercial access indicates the subcutaneous CGRP antibody injection on prescription drug plans with pharmacy benefit coverage for the most lives at or equivalent to Preferred, Covered, Specialty, or Generic on all commercial plans for the preventive treatment of migraine.2 Does not take into consideration any restrictions set forth by individual plans. Data as of 11/2020.
Source: Managed Markets Insight & Technology (MMIT), LLC as of 11/2020 and is subject to change without notice. Please contact the plan or state for the most current information. For commercial insurance and Medicare Part D percentages, please contact the plan or state for the most current information. For Medicaid percentage, please refer to the state’s publicly available PDL for the most current information.
“Coverage” includes all statuses at or equivalent to Preferred, Covered, Specialty, or Generic for the preventive treatment of migraine.
“Preferred” refers to product listing on state’s publicly available PDL.
This information is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures.
Employers and employer groups may also offer additional benefit designs, which may be different than described.
For your eligible, commercially insured patients with migraine or episodic cluster headache,
Get your patients started on Emgality: 1 savings cardb for 2 headache conditions3
Patients can get Emgality for as little as $0 for up to 12 months
Help patients save with the Emgality Savings Cardb
bTerms and Conditions: Offer good until 12/31/2021 for up to 12 months of Emgality. Patients with commercial drug insurance may be able to pay as little as $0 for their first fill of Emgality. For the second and subsequent fills, patients must have coverage for Emgality through their commercial drug insurance plan to continue to pay as little as $0 per fill. Offer subject to a monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and a separate $4900 maximum annual savings. Participation in the program requires a valid patient HIPAA authorization. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. This offer is invalid for patients without commercial drug insurance or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state patient or pharmaceutical assistance program. Offer void where prohibited by law and subject to change or discontinue without notice. Card activation is required. Subject to additional terms and conditions, which can be found here.
PA=prior authorization.
SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
Resources for your practice
Dosing and Prescribing Comparison by Indication
Migraine resources
Emgality Loading Dose Kit (sample)d
The Loading Dose Kit (sample) provides patients with migraine a chance to administer the first monthly dose of Emgality (2 x 120 mg) in their doctor’s office. Loading Dose Kits (samples) are intended to assess tolerability and efficacy for individual patients in the office.
If interested in requesting Emgality 240 mg Loading Dose Kits (samples), please complete and submit your request electronically:
Sample/Sales Representative Request Form
Migraine Patient Questionnaire
Migraine Example Letter of Medical Necessity
Migraine Example Appeal Letter
dSamples are not available for episodic cluster headache.
Episodic cluster headache resources
Episodic Cluster Headache Example Letter of Medical Necessity
Learn more
Register here to receive updates from Lilly.
References: 1. Data on File. Lilly USA, LLC. DOF-GZ-US-0114. 2. Data on File. Lilly USA, LLC. DOF-GZ-US-0111.